|
195 Companies |
|
327 Products |
|
327 Products |
|
167 Mechanisms of Action |
|
13 Trials |
|
3266 News |
|
| «12...1718192021222324252627...6768» |
- New trial: MOrPH: Risk Models to Optimise Prophylaxis Schedules in Children With Haemophilia (clinicaltrials.gov) - Oct 23, 2015
P=N/A, N=20, Not yet recruiting, Sponsor: Neuroscience Research Australia
- Trial primary completion date, Metastases: Vertebral Augmentation and Radiotherapy of Collapse Spinal Metastatic Cancer (clinicaltrials.gov) - Oct 23, 2015
P2, N=20, Recruiting, Sponsor: University of Arizona
Trial primary completion date: Dec 2021 --> Aug 2016
- || Xyntha (moroctocog alfa) / Pfizer
Trial primary completion date: Evaluation Of Acceptability And Satisfaction Of Hemophilia Patients Treated With FusENGO (clinicaltrials.gov) - Oct 23, 2015
P=N/A, N=200, Recruiting, Sponsor: Pfizer
Trial primary completion date: Dec 2021 --> Aug 2016 Trial primary completion date: Jan 2016 --> Dec 2016
- RiaSTAP (fibrinogen concentrate (human)) / CSL Behring
Enrollment open: TOP-CLOT: Trial of RiaSTAP Versus Cryoprecipitate to Lower Operative Transfusions (clinicaltrials.gov) - Oct 23, 2015
P=N/A, N=133, Recruiting, Sponsor: Weill Medical College of Cornell University
Trial primary completion date: Jan 2016 --> Dec 2016 Not yet recruiting --> Recruiting
- New trial: Individualizing Hemophilia Prophylaxis Using Thromboelastography (clinicaltrials.gov) - Oct 23, 2015
P=N/A, N=60, Recruiting, Sponsor: Children's Hospital Los Angeles
- || Enrollment status: OSA in EDS: Obstructive Sleep Apnoea in Ehlers-Danlos Syndrome (clinicaltrials.gov) - Oct 23, 2015
P=N/A, N=100, Enrolling by invitation, Sponsor: University of Zurich
Not yet recruiting --> Recruiting Recruiting --> Enrolling by invitation
- Enrollment status, Trial primary completion date: HOLISTIC: Multidisciplinary Evaluation of Patients With Hemophilia (clinicaltrials.gov) - Oct 23, 2015
P=N/A, N=50, Recruiting, Sponsor: Universidad de Murcia
Recruiting --> Enrolling by invitation Enrolling by invitation --> Recruiting | Trial primary completion date: Jul 2014 --> Nov 2015
- carfilzomib / Generic mfg.
Clinical: Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy (clinicaltrials.gov) - Oct 22, 2015
P2, N=35, Recruiting, Sponsor: Attaya Suvannasankha
Enrolling by invitation --> Recruiting | Trial primary completion date: Jul 2014 --> Nov 2015 Trial primary completion date: Sep 2015 --> Sep 2016
- bortezomib / Generic mfg., melphalan / Generic mfg.
Trial primary completion date: Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma (clinicaltrials.gov) - Oct 22, 2015
P1/2, N=69, Recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Sep 2015 --> Sep 2016 Trial primary completion date: Oct 2015 --> Oct 2016
- || Empliciti (elotuzumab) / AbbVie, BMS
Trial primary completion date, Combination therapy: A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma (clinicaltrials.gov) - Oct 22, 2015
P2, N=102, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Oct 2015 --> Oct 2016 Trial primary completion date: Dec 2015 --> Apr 2016
- Trial primary completion date: UARK 89-001 Phase II Study of Intensive "TOTAL THERAPY" For Untreated or Minimally Treated Patients With Multiple Myeloma (clinicaltrials.gov) - Oct 22, 2015
P2, N=233, Active, not recruiting, Sponsor: University of Arkansas
Trial primary completion date: Dec 2015 --> Apr 2016 Trial primary completion date: Dec 2015 --> Dec 2016
- dinaciclib (MK-7965) / Merck (MSD)
Trial suspension, Combination therapy: Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma (clinicaltrials.gov) - Oct 22, 2015
P1, N=60, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2015 --> Dec 2016 Recruiting --> Suspended
- Kovaltry (octocog alfa) / Bayer, CSL Behring
Enrollment change: Single Dose Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and Advate (clinicaltrials.gov) - Oct 22, 2015
P1, N=8, Active, not recruiting, Sponsor: Bayer
Recruiting --> Suspended N=18 --> 8
- Zolinza (vorinostat) / Merck (MSD)
Enrollment change, Trial termination, Trial primary completion date: Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Oct 22, 2015
P1, N=32, Terminated, Sponsor: UNC Lineberger Comprehensive Cancer Center
N=18 --> 8 N=42 --> 32 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2013 --> Dec 2011; Drugs unavailable- study terminated 1/2/18
- | melphalan / Generic mfg., clarithromycin / Generic mfg.
New P2 trial: CLAIM: Clarithromycin in Multiple Myeloma Induction Therapy (clinicaltrials.gov) - Oct 22, 2015
P2, N=160, Recruiting, Sponsor: Henrik Gregersen
- | befovacimab (BAY 1093884) / Bayer
New P1 trial: A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors (clinicaltrials.gov) - Oct 22, 2015
P1, N=26, Not yet recruiting, Sponsor: Bayer
- |||||| Cablivi (caplacizumab) / Sanofi
Enrollment open: HERCULES: Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura (clinicaltrials.gov) - Oct 22, 2015
P3, N=92, Recruiting, Sponsor: Ablynx
N=42 --> 32 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2013 --> Dec 2011; Drugs unavailable- study terminated 1/2/18 Not yet recruiting --> Recruiting
- Clinical: UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination (clinicaltrials.gov) - Oct 22, 2015
P2, N=30, Not yet recruiting, Sponsor: University of Arkansas
- Enrollment closed, Trial primary completion date: Polymorphism and Auto-reactive B and T Cells Subsets in Adult's Immune Thrombocytopenia (ITP) (clinicaltrials.gov) - Oct 20, 2015
P=N/A, N=43, Active, not recruiting, Sponsor: Assistance Publique - H
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2016 --> Jul 2015
- | alisertib (MLN8237) / Puma, Rituxan (rituximab) / Roche
Enrollment closed, Combination therapy: Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Oct 19, 2015
P2, N=50, Active, not recruiting, Sponsor: Kristie Blum
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2016 --> Jul 2015 Recruiting --> Active, not recruiting
- | Fibryga (fibrinogen concentrate (human)) / Octapharma
Trial completion, Enrollment change: Pharmacokinetic, Efficacy, and Safety Study of Octafibrin Compared to Haemocomplettan/Riastap (clinicaltrials.gov) - Oct 16, 2015
P2, N=22, Completed, Sponsor: Octapharma
Recruiting --> Active, not recruiting Recruiting --> Completed | N=18 --> 22
- | lenalidomide / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Enrollment closed: Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Oct 14, 2015
P1/2, N=45, Active, not recruiting, Sponsor: New York University School of Medicine
Recruiting --> Completed | N=18 --> 22 Recruiting --> Active, not recruiting
- ganetespib (ADX-1612) / Aldeyra
Trial completion, Enrollment change: A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - Oct 13, 2015
P1, N=8, Completed, Sponsor: Emory University
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=15 --> 8
- Enrollment closed, Heterogeneity: Phenotypic Heterogeneity in Hemophilia A: An Investigation of the Role of Platelet Function (clinicaltrials.gov) - Oct 10, 2015
P=N/A, N=42, Active, not recruiting, Sponsor: CancerCare Manitoba
Active, not recruiting --> Completed | N=15 --> 8 Recruiting --> Active, not recruiting
- | carfilzomib / Generic mfg.
Clinical: Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib (clinicaltrials.gov) - Oct 9, 2015
P2, N=36, Active, not recruiting, Sponsor: Ajai Chari
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Farydak (panobinostat) / Secura Bio
Enrollment closed, Combination therapy: Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM) (clinicaltrials.gov) - Oct 9, 2015
P2, N=27, Active, not recruiting, Sponsor: Ajai Chari
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Farydak (panobinostat) / Secura Bio
Clinical: Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma (clinicaltrials.gov) - Oct 8, 2015
P1, N=23, Active, not recruiting, Sponsor: Emory University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=48 --> 23 | Trial primary completion date: Jul 2015 --> Aug 2016
- | bortezomib / Generic mfg., cyclophosphamide / Generic mfg., thalidomide / Generic mfg.
Trial completion: Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04) (clinicaltrials.gov) - Oct 7, 2015
P3, N=358, Completed, Sponsor: Nantes University Hospital
Recruiting --> Active, not recruiting | N=48 --> 23 | Trial primary completion date: Jul 2015 --> Aug 2016 Active, not recruiting --> Completed
- marizomib (NPI-0052) / Triphase Accelerator Corporation, BMS
Clinical: Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov) - Oct 6, 2015
P1, N=36, Recruiting, Sponsor: Triphase Research and Development I Corporation
Active, not recruiting --> Completed Trial primary completion date: Sep 2015 --> Jan 2016
- | olaptesed pegol (NOX-A12) / TME Pharma
Trial completion, Combination therapy: NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma (clinicaltrials.gov) - Oct 6, 2015
P2a, N=28, Completed, Sponsor: NOXXON Pharma AG
Trial primary completion date: Sep 2015 --> Jan 2016 Active, not recruiting --> Completed
- sotatercept (MK-7962) / BMS, Merck (MSD)
Trial primary completion date: A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma (clinicaltrials.gov) - Oct 6, 2015
P2a, N=20, Recruiting, Sponsor: Rebecca Silbermann
Active, not recruiting --> Completed Trial primary completion date: Oct 2015 --> Jan 2016
- Kymriah (tisagenlecleucel-T) / Novartis
Trial completion, Trial primary completion date: CART-19 for Multiple Myeloma (clinicaltrials.gov) - Oct 5, 2015
P1, N=13, Completed, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Trial primary completion date: Oct 2015 --> Jan 2016 Recruiting --> Completed | Trial primary completion date: May 2016 --> Sep 2015
- ||| New trial: Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S) (clinicaltrials.gov) - Oct 5, 2015
P=N/A, N=300, Not yet recruiting, Sponsor: Novo Nordisk A/S
- | Trial completion: UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin (clinicaltrials.gov) - Oct 5, 2015
P3, N=180, Completed, Sponsor: University of Arkansas
Recruiting --> Completed | Trial primary completion date: May 2016 --> Sep 2015 Recruiting --> Completed
- | Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi
New P2 trial: SHIVERING 2: Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients (clinicaltrials.gov) - Oct 2, 2015
P2, N=150, Recruiting, Sponsor: Yale University
- | staphylococcal protein A (PRTX-100) / Protalex
New P1/2 trial: PRTX-100-203 Open-Label, Dose Escalation Study in Adult Patients With ITP (clinicaltrials.gov) - Oct 2, 2015
P1/2, N=30, Not yet recruiting, Sponsor: Protalex, Inc.
- || melphalan / Generic mfg., carfilzomib / Generic mfg.
BRCA Biomarker: Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Oct 2, 2015
P1/2, N=58, Recruiting, Sponsor: University of Alabama at Birmingham
Recruiting --> Completed Trial primary completion date: Nov 2014 --> Nov 2016
- || Empliciti (elotuzumab) / AbbVie, BMS
Trial primary completion date, Combination therapy: A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma (clinicaltrials.gov) - Oct 1, 2015
P2, N=102, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Nov 2014 --> Nov 2016 Trial primary completion date: Apr 2015 --> Dec 2015
- Enrollment closed, Trial primary completion date: Human Fibrinogen Concentrate (FGTW) in Pediatric Patients With Congenital Fibrinogen Deficiency (clinicaltrials.gov) - Oct 1, 2015
P2/3, N=16, Active, not recruiting, Sponsor: Laboratoire français de Fractionnement et de Biotechnologies
Trial primary completion date: Apr 2015 --> Dec 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Dec 2015
- lenalidomide / Generic mfg.
Trial completion, Trial primary completion date: Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell Transplant (clinicaltrials.gov) - Oct 1, 2015
P2, N=18, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Dec 2015 Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Aug 2015
- Targretin oral (bexarotene oral) / ReXceptor, efatutazone (CS-7017) / Daiichi Sankyo
Enrollment change, Trial termination: Phase I Study of CS-7017 and Bexarotene (clinicaltrials.gov) - Sep 30, 2015
P1, N=9, Terminated, Sponsor: Georgetown University
Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Aug 2015 N=22 --> 9 | Recruiting --> Terminated; Drug no longer available
- | Xyntha (moroctocog alfa) / Pfizer
Trial completion: Study of PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Male Chinese Subjects With Hemophilia A (clinicaltrials.gov) - Sep 29, 2015
P1, N=13, Completed, Sponsor: Pfizer
N=22 --> 9 | Recruiting --> Terminated; Drug no longer available Recruiting --> Completed
- Nplate (romiplostim) / Amgen, Kyowa Kirin
Trial primary completion date: Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy (clinicaltrials.gov) - Sep 25, 2015
P2, N=14, Suspended, Sponsor: New York University School of Medicine
Recruiting --> Completed Trial primary completion date: Aug 2015 --> Dec 2015
- TevaGrastim (filgrastim biosimilar) / Nippon Kayaku, Teva, Mozobil (plerixafor) / Sanofi
Trial primary completion date, Combination therapy, Head-to-Head: Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma (clinicaltrials.gov) - Sep 25, 2015
P2, N=100, Recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Aug 2015 --> Dec 2015 Trial primary completion date: Aug 2015 --> Dec 2015
- Willfact (human von Willebrand factor) / LFB Biotechnologies
Trial primary completion date: Willebrand International Non-interventional Global Surveillance (clinicaltrials.gov) - Sep 25, 2015
P=N/A, N=80, Recruiting, Sponsor: Laboratoire français de Fractionnement et de Biotechnologies
Trial primary completion date: Aug 2015 --> Dec 2015 Trial primary completion date: Dec 2017 --> Dec 2018
- luminespib (AUY922) / Ligand
Trial primary completion date: HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET (clinicaltrials.gov) - Sep 24, 2015
P2, N=7, Terminated, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Dec 2017 --> Dec 2018 Trial primary completion date: Aug 2015 --> May 2015
- || Zelboraf (vemurafenib) / Roche
Trial primary completion date: A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers (clinicaltrials.gov) - Sep 24, 2015
P2, N=160, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Aug 2015 --> May 2015 Trial primary completion date: Apr 2017 --> Sep 2016
- Vesanoid (tretinoin) / Roche
Enrollment change, Trial termination, Trial primary completion date: Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Sep 24, 2015
P1/2, N=2, Terminated, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Apr 2017 --> Sep 2016 N=70 --> 2 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2018 --> Sep 2015; Terminated Phase I due to slow accrual without progression to Phase II.
- bortezomib / Generic mfg.
Enrollment open, Trial primary completion date: UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma (clinicaltrials.gov) - Sep 24, 2015
P2, N=30, Recruiting, Sponsor: University of Arkansas
N=70 --> 2 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2018 --> Sep 2015; Terminated Phase I due to slow accrual without progression to Phase II. Active, not recruiting --> Recruiting | Trial primary completion date: Dec 2015 --> Dec 2016
- ||||| New P4 trial: HOLA: Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America (clinicaltrials.gov) - Sep 24, 2015
P4, N=8100, Recruiting, Sponsor: Janssen-Cilag Ltd.